Akari Therapeutics Stock (NASDAQ: AKTX) stock price, news, charts, stock research, profile.
Open | $1.200 |
Close | - |
Volume / Avg. | 3.360K / 11.672K |
Day Range | 1.170 - 1.200 |
52 Wk Range | 1.078 - 5.500 |
Market Cap | $8.954M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 34 |
Short Interest | 0.22% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Akari Therapeutics (NASDAQ: AKTX) through any online brokerage.
Other companies in Akari Therapeutics’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Virios Therapeutics (NASDAQ:VIRI), Can Fite Biofarma (AMEX:CANF), BioRestorative Therapies (NASDAQ:BRTX) and NuCana (NASDAQ:NCNA).
The latest price target for Akari Therapeutics (NASDAQ: AKTX) was reported by HC Wainwright & Co. on Monday, December 5, 2022. The analyst firm set a price target for 1.50 expecting AKTX to rise to within 12 months (a possible 32.74% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Akari Therapeutics (NASDAQ: AKTX) is $1.13 last updated April 17, 2024 at 8:26 AM EDT.
There are no upcoming dividends for Akari Therapeutics.
Akari Therapeutics’s FY earnings are confirmed for Monday, April 1, 2024.
There is no upcoming split for Akari Therapeutics.
Akari Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.